Researchers are studying ways to help adults manage cannabis withdrawal symptoms — and they need your help.
Adults ages 18–55 who have been diagnosed with cannabis use disorder may be eligible to take part in a paid clinical research study in the United States.
What is this study?
This is a Phase 3 clinical research study looking at whether an investigational medicine may help reduce cannabis withdrawal symptoms in adults with cannabis use disorder (CUD).
The study is randomized and double-blind, meaning neither you nor the study team will know which study treatment you are assigned to receive.
The study is sponsored by a pharmaceutical company and is conducted in accordance with Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki.
Researchers are seeking adults ages 18–55 across the United States who meet the study's eligibility criteria.
Study at a Glance
- Study Phase
- Phase 3
- Condition
- Cannabis Use
Disorder (CUD) - Study Design
- Randomized,
Double-Blind - Inpatient Stay
- ~7 Days
- Total Duration
- ~10 Weeks
- Standards
- GCP &
Declaration of Helsinki
Who Can Participate?
You may be eligible for this study if you meet the following criteria:
Adults ages 18 to 55 years old
Have received a diagnosis of cannabis use disorder (CUD) based on DSM-5 criteria, confirmed by a qualified study clinician
Currently use cannabis regularly and are willing to stop cannabis use after the study randomization date
Must have used cannabis during the Screening period, including on the day before randomization
Urine drug screen must be positive for THC at Screening and on the day of randomization
Urine drug screen must be negative for all other excluded or illicit substances at Screening and on the day of randomization, and negative for alcohol on the day of randomization
Think you might be a good fit?
Take a few minutes to see if this study is right for you.
Who Should Not Participate?
This study may not be suitable for you if any of the following apply:
Individuals younger than 18 or older than 55 years of age
Individuals with a lifetime history of a DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
Individuals who meet DSM-5 criteria for any current or past substance use disorder other than cannabis use disorder or nicotine use disorder
Individuals currently pregnant or breastfeeding, or who are unwilling to use acceptable contraception during the study
Individuals who have tested positive for illicit or excluded substances (other than cannabis/THC) at Screening or on the day of randomization
Individuals with a positive urine alcohol test on the day of randomization
What's Involved?
The study lasts approximately 10 weeks in total, including a screening period, a mandatory inpatient stay, outpatient visits, and a follow-up call.
Week 1 (Days 1–7)
Inpatient Stay
You will stay at an inpatient research unit for approximately 7 days (overnight stays on Days 1 through 6), where the study team will monitor your health and administer the study medicine.
Weeks 2–7 (Days 8–49)
Outpatient Visits
After discharge, you will attend outpatient clinic visits and complete daily evening video check-in calls with the study team through approximately Day 35, plus additional clinic visits through Day 49.
Day 64 (approximately)
Follow-Up Call
A telephone follow-up call will take place approximately 30 days after your last dose to check on your health.
Compensation
Compensation may be provided for time and travel.
